Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20265 Citations
Cartalax is a tripeptide bioregulator (AED) targeting cartilage tissue at the gene expression level. Preclinical data shows chondrocyte proliferation and MMP-9 inhibition in rat models. No human trials exist. The small community using it reports subtle joint stiffness improvements over 30-day oral courses.
10mcg · Daily
Summary: Add 0mL BAC water to your 20mg vial. Draw to < 0.1 units on a U-100 syringe for a 10mcg dose. This vial will last 0 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | Daily |
| Moderate | 20mg | Daily |
| Aggressive | 20mg | 2x Daily |
Cartalax is an oral capsule. No reconstitution, no syringes, no bacteriostatic water for the standard protocol. You take 1 to 2 Cytogen capsules (10 to 20 mg) daily for 30 days, then stop for 3 to 6 months. That long off-period is built into the Khavinson model; the theory holds that epigenetic changes persist well beyond the dosing window. Watch the labeling. Some vendors list "0.1 mg" per capsule (pure AED peptide weight) while others list "10 mg" (total peptide complex weight). That is a 100x difference in apparent dose. Confirm which measurement your vendor uses before adjusting anything. If you go the injectable route (research use only, no clinical validation), reconstitute a 20 mg vial with 2 mL bacteriostatic water for 10 mg/mL concentration. On a U-100 insulin syringe, 100 units equals the full 10 mg dose. Each vial covers two injections at 10 mg per day, or one injection per day for 14 days if you split into two vials. Injectable courses run 10 to 14 days, shorter than oral. Source oral capsules from established Russian vendors (Cytogen/GARMONIA via CosmicNootropic or ipept.com). For injectable vials, request a COA with HPLC purity at or above 98 percent and mass spec confirmation of the AED sequence.
Dosing based on Khavinson Institute protocol — 6 published references.View all sources →
Cross-check your Cartalax reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Cartalax is a tripeptide bioregulator (AED) targeting cartilage tissue at the gene expression level. Preclinical data shows chondrocyte proliferation and MMP-9 inhibition in rat models. No human trials exist. The small community using it reports subtle joint stiffness improvements over 30-day oral courses.